Lipids

, Volume 47, Issue 11, pp 1053–1062

High Serum Palmitic Acid is Associated with Low Antiviral Effects of Interferon-Based Therapy for Hepatitis C Virus

  • Teruki Miyake
  • Yoichi Hiasa
  • Masashi Hirooka
  • Yoshio Tokumoto
  • Takao Watanabe
  • Shinya Furukawa
  • Teruhisa Ueda
  • Shin Yamamoto
  • Teru Kumagi
  • Hiroaki Miyaoka
  • Masanori Abe
  • Bunzo Matsuura
  • Morikazu Onji
Original Article

DOI: 10.1007/s11745-012-3716-8

Cite this article as:
Miyake, T., Hiasa, Y., Hirooka, M. et al. Lipids (2012) 47: 1053. doi:10.1007/s11745-012-3716-8

Abstract

Hepatitis C virus (HCV) infection alters fatty acid synthesis and metabolism in association with HCV replication. The present study examined the effect of serum fatty acid composition on interferon (IFN)-based therapy. Fifty-five patients with HCV were enrolled and received IFN-based therapy. Patient characteristics, laboratory data (including fatty acids), and viral factors that could be associated with the anti-HCV effects of IFN-based therapy were evaluated. The effects of individual fatty acids on viral replication and IFN-based therapy were also examined in an in-vitro system. Multivariate logistic regression analysis showed that the level of serum palmitic acid before treatment and HCV genotype were significant predictors for rapid virological response (RVR), early virological response (EVR), and sustained virological response (SVR). High levels of palmitic acid inhibited the anti-HCV effects of IFN-based therapy. HCV replication assays confirmed the inhibitory effects of palmitic acid on anti-HCV therapy. The concentration of serum palmitic acid is an independent predictive factor for RVR, EVR, and SVR in IFN-based antiviral therapy. These results suggest that the effect of IFN-based antiviral therapy in patients with HCV infection might be enhanced by treatment that modulates palmitic acid levels.

Keywords

Fatty acidHepatitis C virusInterferonPalmitic acidVirological response

Abbreviations

AUC

Area under curve

BMI

Body mass index

DMEM

Dulbecco’s modified Eagle’s medium

EVR

Early virological response

GAPDH

Glyceraldehyde-3-phosphate dehydrogenase

HCC

Hepatocellular carcinoma

HBc

Hepatitis B core

HBs-Ag

Hepatitis B surface antigen

HBV

Hepatitis B virus

HCV

Hepatitis C virus

IFN

Interferon

IL-28B

Interleukin-28B

ISDR

Interferon sensitivity-determining region

NPV

Negative predictive value

NS5

Nonstructural-5

PEG-IFN

Pegylated interferon

PPV

Positive predictive value

RBV

Ribavirin

ROC

Receiver operating characteristics

RVR

Rapid virological response

SVR

Sustained virological response

PCR

Polymerase chain reaction

Supplementary material

11745_2012_3716_MOESM1_ESM.doc (186 kb)
Supplementary material 1 (DOC 185 kb)
11745_2012_3716_MOESM2_ESM.pdf (291 kb)
Supplementary material 2 (PDF 290 kb)
11745_2012_3716_MOESM3_ESM.pdf (351 kb)
Supplementary material 3 (PDF 351 kb)

Copyright information

© AOCS 2012

Authors and Affiliations

  • Teruki Miyake
    • 1
  • Yoichi Hiasa
    • 1
  • Masashi Hirooka
    • 1
  • Yoshio Tokumoto
    • 1
  • Takao Watanabe
    • 1
  • Shinya Furukawa
    • 1
  • Teruhisa Ueda
    • 1
  • Shin Yamamoto
    • 1
  • Teru Kumagi
    • 1
  • Hiroaki Miyaoka
    • 2
  • Masanori Abe
    • 1
  • Bunzo Matsuura
    • 1
  • Morikazu Onji
    • 1
  1. 1.Department of Gastroenterology and MetabologyEhime University Graduate School of MedicineToonJapan
  2. 2.Internal MedicineSaiseikai Matsuyama HospitalMatsuyamaJapan